Login to Your Account

Novabiotics sees preclinical potential in S. aureus killer

By Michael Fitzhugh
Staff Writer

Friday, June 2, 2017

NEW ORLEANS – A preclinical antibiotic candidate under development at Novabiotics Ltd. called Luminaderm could potentially offer clinicians a new way to head off troublesome nasal Staphylococcus aureus infections.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription